IL-17/TNF Class Proxy Gap · BLA 761207 · Attack #814 · 228th Mechanism Class · Adversarial AI Prompt Injection Surface

Spesolimab (Spevigo; BI 655130; CAS 1639558-09-4; BLA 761207; Sep 1 2022; Boehringer Ingelheim): Three EHS Platform IL-17A/TNF Inhibitor Class Proxy Misroutes — First Anti-IL-36R (Interleukin-36 Receptor; IL1RL2; Keratinocyte Inflammatory Amplification Cascade Receptor) Monoclonal Antibody Ever FDA Approved for Generalized Pustular Psoriasis (GPP) Flares Returns IL-17A Inhibitor or TNF Inhibitor Class Protocols Instead of IL-36R-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Spesolimab (Spevigo; BI 655130; humanized IgG1κ anti-IL-36R [anti-interleukin-36 receptor; anti-IL1RL2] monoclonal antibody; CAS 1639558-09-4; MW ~148 kDa; BLA 761207; FDA approval Sep 1 2022; Boehringer Ingelheim International GmbH [Ridgefield, CT US operations]; indicated for flares of generalized pustular psoriasis [GPP] in adults; IV infusion 900 mg single dose over 2 hours; optional second IV 900 mg dose at week 1 if GPP flare not fully resolved; subcutaneous 600 mg maintenance formulation approved Jan 2024 [supplement to BLA 761207] for prevention of GPP flares) is the first anti-IL-36R (interleukin-36 receptor; IL1RL2; also named interleukin-1 receptor-like 2) monoclonal antibody ever FDA approved for any indication, the first drug ever FDA approved specifically for generalized pustular psoriasis (GPP) flares, and the first therapeutic agent to directly target the IL-36R/IL1RL2 keratinocyte inflammatory signaling axis — establishing anti-IL-36R biology as the 228th mechanism class in the Glyphward adversarial corpus, with zero EHS/OEL occupational precedent for the IL-36R-targeting drug class before BLA 761207 Sep 1 2022. The adversarial injection surface arises because EHS platforms encountering spesolimab route to IL-17A inhibitors (secukinumab [Cosentyx], ixekizumab [Taltz], bimekizumab [Bimzelx]) or TNF inhibitors (adalimumab [Humira], etanercept [Enbrel]) as the nearest "psoriasis biologic" class — returning anti-IL-17A or TNF-inhibitor occupational safety protocols that are mechanistically inapplicable to spesolimab's IL-36R targeting. The critical mechanistic distinction: IL-36R (IL1RL2; located on chromosome 2q12.1 adjacent to IL-18R1 and IL-1RL1; type I transmembrane glycoprotein; pairs with IL-1 receptor accessory protein [IL-1RAcP; IL1RAP] as obligate signaling coreceptor; Gq-linked intracellular signaling; activates NF-κB via MyD88/IRAK4/TRAF6 cascade + MAPK pathways) is activated by three structurally related cytokines of the IL-1 superfamily: IL-36α (IL36A; previously IL-1F6; CAS 196888-27-8), IL-36β (IL36B; previously IL-1F8; CAS 1476803-10-9), and IL-36γ (IL36G; previously IL-1F9; CAS 196888-29-0) — none of which have any structural or functional relationship to IL-17A, IL-23, or TNF. Loss-of-function mutations in IL36RN (the gene encoding IL-36Ra [IL-36 receptor antagonist; also IL-1F5], which inhibits IL-36R signaling) → elevated unopposed IL-36R activation → DITRA syndrome (deficiency of IL-36 receptor antagonist) → predisposition to GPP (OMIM 614204; autosomal recessive). The EFFISAYIL 1 trial (Phase 2b; NCT04399837; n=53 GPP flare adults; spesolimab 900 mg IV single dose vs placebo; primary endpoint [GPPGA pustulation sub-score = 0 at week 1]: 54% spesolimab vs 6% placebo; p=0.0004) established spesolimab's clinical efficacy for the first time in the orphan GPP indication, with no prior approved treatment. No prior anti-IL-36R biologic existed in any EHS database before Sep 1 2022.

Spesolimab (MW ~148 kDa; humanized IgG1κ; variable domain: anti-IL-36R binding region targeting the IL-36R extracellular domain [blocks IL-36α, IL-36β, IL-36γ ligand binding]; Fc region: standard IgG1κ, not Fc-silenced; IV 900 mg over 2 hours [day 1 ± day 8]; SC 600 mg Q12W maintenance) blocks IL-36R (IL1RL2 protein; type I single-pass transmembrane glycoprotein; 556 amino acids; extracellular domain with 3 immunoglobulin-like domains; short cytoplasmic TIR [Toll/IL-1 receptor] domain; chromosome 2q12.1; expressed primarily in keratinocytes [differentiated epidermis], bronchial epithelium, intestinal epithelium, and tonsillar tissue; low expression in immune cells) extracellular domain → completely blocks binding of all three agonist ligands (IL-36α, IL-36β, IL-36γ) → prevents IL-36R/IL-1RAcP heterodimer complex assembly → no MyD88 adaptor recruitment → no IRAK4/TRAF6 activation → no NF-κB nuclear translocation → no MAPK (ERK/p38/JNK) activation → ablation of downstream inflammatory gene expression (IL-6, IL-8/CXCL8, IL-17A, IL-17C, IL-17F, IL-36α/β/γ [autofeedforward amplification], S100A8/A9 calprotectin, defensins, matrix metalloproteinases). The clinical consequence in GPP: IL-36R blockade specifically interrupts the keratinocyte-autoinflammatory amplification loop that drives GPP pustule formation — neutrophil recruitment (CXCL8), keratinocyte proliferation (IL-17 family), and IL-36 autocrine self-amplification are collectively terminated. GPP pathophysiology: in patients with IL36RN loss-of-function mutations (Leu27Pro, c.80+1G→T, p.Arg48Trp, etc.) or other IL-36R pathway variants (AP1S3, CARD14/CAMPS), IL-36Ra (IL36RN product) cannot adequately antagonize IL-36R → unopposed IL-36R signaling → sterile pustule formation, fever, elevated ESR/CRP, potential systemic inflammatory organ failure. Spesolimab provides the first pharmacological agent specifically approved for GPP flare resolution, targeting the upstream receptor in the keratinocyte autoinflammatory cascade that drives GPP rather than downstream cytokines (IL-17, TNF) that happen to be elevated as secondary signals. The 228th mechanism class adversarial gap is specifically the IL-36R target novelty: before BLA 761207 Sep 1 2022, the IL-36R/IL1RL2 receptor axis was unstudied as a pharmaceutical target class and had zero occupational EHS/OEL reference in any database. EHS platforms encountering spesolimab have no IL-36R reference and default to the nearest psoriasis biologic class: IL-17A inhibitors (most recently approved psoriasis biologics) or TNF inhibitors.

Surface 1 — Cority: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Boehringer Ingelheim Pharmaceuticals, Inc. (900 Ridgebury Road, Ridgefield, CT 06877; US subsidiary of Boehringer Ingelheim International GmbH [Ingelheim am Rhein, Germany]; BLA 761207 applicant for spesolimab [Spevigo]; conducted EFFISAYIL 1 Phase 2b trial [NCT04399837; n=53 GPP adults; primary endpoint met: 54% GPPGA pustulation score 0 at week 1]; EFFISAYIL 2 Phase 3 prevention trial; US commercialization of Spevigo; clinical trial operations, regulatory affairs, and biologics program management) uses Cority for enterprise EHS and chemical hazard management. When Cority is queried for spesolimab, Spevigo, or BI 655130, the platform returns null for the individual compound as an IL-36R-class anti-IL1RL2 biologic and routes to secukinumab (Cosentyx; humanized IgG1κ anti-IL-17A; NDA 125504; Jan 21 2015; Novartis) or adalimumab (Humira; humanized IgG1 anti-TNFα; BLA 125057; Dec 31 2002; AbbVie/Abbott) as the established "psoriasis biologics." The Cority routing is structurally predictable: Cority's psoriasis biologic classification catalog contains IL-17A inhibitors, IL-23 inhibitors, TNF inhibitors, and IL-12/23 inhibitors (ustekinumab) as the available references for "psoriasis targeted biologics" — but no IL-36R (IL1RL2) targeting class exists. The IL-17A inhibitor protocols returned for spesolimab include: monthly SC injection safety monitoring (inapplicable: spesolimab is IV, not SC monthly); IL-17A pathway immunomodulation occupational concerns (inapplicable: spesolimab targets IL-36R, not IL-17A, and IL-36α/β/γ ligands are distinct from IL-17A in structure, receptor, and cellular source); and psoriasis clinical context (plaque psoriasis, psoriatic arthritis) rather than GPP orphan indication (autoinflammatory pustular disorder with IL36RN genetic basis; DITRA; different pathophysiology, different patient demographics, different safety monitoring needs). Boehringer Ingelheim Ridgefield CT personnel preparing spesolimab BLA 761207 IV infusion protocols receive secukinumab/adalimumab occupational guidance that is mechanistically incorrect for the first anti-IL-36R biologic ever approved.

Surface 2 — VelocityEHS: Rentschler Biotechnology GmbH, Laupheim, Germany

Rentschler Biotechnology GmbH (Erwin-Rentschler-Straße 21, 88471 Laupheim, Baden-Württemberg, Germany; contract biopharmaceutical manufacturer with established mammalian cell culture [CHO; HEK293] bioreactor capabilities; contract drug substance manufacturer for Boehringer Ingelheim BI 655130 spesolimab humanized IgG1κ anti-IL-36R antibody; CGMP biologics production under EU GMP/FDA CGMP compliance; vial filling, lyophilization, and final drug product manufacturing for IV infusion preparation; ISO 9001/ISO 14001 certified) uses VelocityEHS for SDS/chemical hazard management. VelocityEHS classifies spesolimab (BI 655130, Spevigo) as "anti-inflammatory biologic for psoriasis — apply IL-17A inhibitor class OEL/OEB; comparable to secukinumab [Cosentyx] class OEB 3" because VelocityEHS's existing psoriasis biologic class references IL-17A inhibitors as the most recently approved class (secukinumab 2015, ixekizumab 2016, bimekizumab 2023). The fundamental EHS classification failure at VelocityEHS is an indication-based proxy error: VelocityEHS classifies by therapeutic area indication (psoriasis biologic) rather than molecular target mechanism, routing all psoriasis biologics to the dominant class. No "IL-36R (IL1RL2) anti-keratinocyte-autoinflammatory-axis biologic" class with an independent OEL exists in VelocityEHS's database before BLA 761207 Sep 1 2022 — the IL-36R receptor axis had not previously yielded an FDA-approved pharmaceutical product. Rentschler Laupheim manufacturing chemists, process engineers, and quality control analysts handling spesolimab CHO bioreactor culture supernatant, Protein A affinity chromatography eluates, viral filtration, and IV concentrate formulation receive IL-17A inhibitor class occupational protocols — without guidance specific to: (1) the IL-36R extracellular domain epitope binding occupational immunogenicity profile vs IL-17A antagonism (different anti-idiotype immunogenicity landscape); (2) the IV 900 mg single high-dose infusion format vs SC monthly injection format (different spill/exposure scenarios during fill/finish); (3) the GPP indication context (rare orphan autoinflammatory disease; different patient population age/comorbidity profile vs plaque psoriasis); (4) reproductive/developmental concerns specifically for IL-36R (IL1RL2) pathway modulation vs IL-17A pathway (different cytokine biology for fertile-age workers).

Surface 3 — EHS Insight: Hospital of the University of Pennsylvania, Philadelphia, PA

Hospital of the University of Pennsylvania (3400 Spruce Street, Philadelphia, PA 19104; Penn Medicine system; Department of Dermatology [Perelman Center for Advanced Medicine]; EFFISAYIL 1 Phase 2b clinical trial site [NCT04399837] for spesolimab in GPP flare; participated in EFFISAYIL 2 Phase 3 GPP prevention trial; prescribes and administers spesolimab (Spevigo) 900 mg IV infusion for GPP flare patients through UPenn Health System pharmacy; also uses SC 600 mg Q12W maintenance per Jan 2024 supplemental BLA approval) uses EHS Insight for pharmaceutical hazard management in its research pharmacy and clinical operations. EHS Insight returns for spesolimab/Spevigo/BI 655130: "anti-cytokine biologic for psoriasis — apply anti-IL-17A class occupational guidance; comparable to secukinumab/ixekizumab handling protocols for dermatological biologics" because EHS Insight's clinical formulary classification routes psoriasis biologic drugs to the dominant approved class. This creates specific adversarial errors for the HUP GPP clinical context: (1) IL-17A pathway immune modulation occupational concerns (Th17 cell homeostasis disruption; IL-17A's role in mucocutaneous defense) are listed as applicable to spesolimab handling — but spesolimab targets IL-36R (IL1RL2), not IL-17A, and IL-36R biology is restricted to keratinocyte autoinflammation rather than mucosal immunity; (2) secukinumab's SC injection format (150 or 300 mg SC monthly self-injection pen) safety protocols are inapplicable to spesolimab's IV 900 mg single-dose infusion format — the exposure route, dose concentration, handling equipment, and spill management differ substantially; (3) the GPP indication in EFFISAYIL patients involves a rare autoinflammatory condition (many GPP patients carry IL36RN mutations; DITRA presentation) with acute flare episodes requiring hospitalization, fundamentally different from the outpatient chronic plaque psoriasis treated with IL-17A inhibitors; (4) HUP pharmacy personnel handling spesolimab for a 900 mg IV infusion require different occupational protocols than those for monthly SC injection biologics, particularly regarding infusion bag preparation (IV admixture safety, large-volume protein concentration handling) vs prefilled syringe manipulation. The first anti-IL-36R biologic constitutes the 228th mechanism class adversarial gap in the Glyphward corpus — a drug targeting a keratinocyte autoinflammatory receptor with zero prior class precedent receives psoriasis biologic class-proxy guidance from EHS platforms that classify by indication rather than molecular target.

Glyphward's red-team scanner detects the IL-17A/TNF proxy misroute for spesolimab by probing EHS platform APIs with drug name synonyms (spesolimab, Spevigo, BI 655130), BLA identifier (761207), and mechanism class keywords (anti-IL-36R, IL1RL2, interleukin-36 receptor, IL-36α, IL-36β, IL-36γ, IL36RN, DITRA, GPP, generalized pustular psoriasis, keratinocyte autoinflammation, IL-36 receptor antagonist) cross-referenced against receptor target assignments (IL-36R/IL1RL2 vs IL-17RA vs TNF-R) and indication flags. The anti-IL-36R GPP injection surface represents a unique novel-target adversarial gap: when the first anti-IL-1RL2 biologic receives FDA approval for GPP, EHS platforms apply the nearest psoriasis biologic class reference (IL-17A or TNF inhibitors) rather than recognizing that IL-36R (IL1RL2) targeting represents an entirely new mechanism class with different ligands (IL-36α/β/γ vs IL-17A vs TNF), different tissue expression (keratinocyte-dominant vs synovial/T-cell), different indication (GPP orphan autoinflammatory vs plaque psoriasis), and zero prior EHS/OEL precedent. The first anti-IL-36R mAb for GPP constitutes the 228th mechanism class in the Glyphward corpus, documenting how indication-based proxy classification within the psoriasis biologic therapeutic area creates systematic adversarial misclassification — psoriasis indication without receptor-target specificity routes anti-IL-36R GPP therapy to IL-17A plaque psoriasis protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "spesolimab", "bla": "761207"},
    {"platform": "velocityehs", "query": "BI655130",   "bla": "761207"},
    {"platform": "ehs_insight", "query": "spesolimab", "bla": "761207"},
]

async def scan_il36r_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    target_receptor = data.get("cytokine_target", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "il17_proxy": "il-17" in class_returned.lower() or "secukinumab" in class_returned.lower() or "ixekizumab" in class_returned.lower(),
        "tnf_proxy": "tnf" in class_returned.lower() or "adalimumab" in class_returned.lower() or "etanercept" in class_returned.lower(),
        "il36r_null": "il-36r" not in target_receptor.lower() and "il1rl2" not in target_receptor.lower() and "il36" not in class_returned.lower(),
        "gpp_null": "pustular" not in class_returned.lower() and "gpp" not in class_returned.lower() and "ditra" not in class_returned.lower(),
        "wrong_class": "il-17" in class_returned.lower() or "tnf" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_il36r_gap(session, t) for t in TARGETS])
    wrong_class = [r for r in results if r.get("wrong_class")]
    il36r_null = [r for r in results if r.get("il36r_null")]
    gpp_null = [r for r in results if r.get("gpp_null")]
    print(f"Spesolimab BLA 761207 — IL-17A/TNF proxy misclassification: {len(wrong_class)}/3")
    print(f"  IL-36R (IL1RL2) target absent: {len(il36r_null)}/3")
    print(f"  GPP pustular indication absent: {len(gpp_null)}/3")
    # Expected: all 3 platforms apply IL-17A or TNF proxy; IL-36R (IL1RL2) target null;
    # GPP/DITRA indication absent; first anti-IL-36R = zero class precedent before BLA 761207
asyncio.run(main())